GlassScriptPhysician profile
Robyn L Haithcock
NPI 1497751994
$7,767.47
in general payments reported to CMS, 2019-2025
30 companies · $275 in 2025
The $275 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $651 · 2021: $1,379 · 2022: $2,036 · 2023: $2,100 · 2024: $726 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,084 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,084.43 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,366.36 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $831.05 | 2019-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $723.77 | 2021-2024 | Stelara |
| Gilead Sciences, INC. | $581.93 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $549.51 | 2019-2024 | Entyvio, Gattex |
| Novo Nordisk INC | $307.59 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $228.13 | 2019-2024 | |
| Celgene Corporation | $200.08 | 2021-2024 | Zeposia |
| Pfizer INC. | $190.84 | 2019-2024 | |
| Qol Medical, LLC | $182.03 | 2019-2024 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $175.32 | 2019-2024 | Dificid |
| Braintree Laboratories, INC. | $171.59 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $160.56 | 2019-2024 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $142.24 | 2024-2025 | Voquezna |
| Amgen INC. | $124.36 | 2020-2023 | Avsola, Amjevita |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $121.82 | 2025 | Arexvy |
| E.R. Squibb & Sons, L.L.C. | $116.37 | 2022 | |
| Nestle Healthcare Nutrition INC. | $95.02 | 2020-2023 | |
| Madrigal Pharmaceuticals | $77.87 | 2025 | Rezdiffra |
| Genzyme Corporation | $73.19 | 2023 | |
| Redhill Biopharma INC. | $68.97 | 2020-2021 | |
| Concordia Pharmaceuticals INC. | $60.34 | 2019 | |
| Shionogi INC | $57.76 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $46.21 | 2023 | Dupixent |
| Aimmune Therapeutics, INC. | $33.19 | 2024 | |
| Lilly USA, LLC | $21.84 | 2024 | |
| Ferring Pharmaceuticals INC. | $16.87 | 2023 | Rebyota |
| Shire North American Group INC | $16.81 | 2019 | |
| Allergan, INC. | $13.76 | 2019 | |
| Ucb, INC. | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robyn Haithcock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.